Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
KADIA, TAPAN MAHENDRA
One or more keywords matched the following items that are connected to KADIA, TAPAN MAHENDRA
Item TypeName
Concept Isocitrate Dehydrogenase
Academic Article Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.
Academic Article Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
Academic Article Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
Academic Article Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
Academic Article Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
Academic Article Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Academic Article Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
Academic Article Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Academic Article Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Academic Article Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
Academic Article Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Academic Article A Phase Ib/II Study of Ivosidenib with Venetoclax ? Azacitidine in IDH1-Mutated Myeloid Malignancies.
Academic Article Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
Search Criteria
  • Isocitrate Dehydrogenase